Posts

How LB Pharmaceuticals Rode Brutal Capital Markets to One of 2025's Most Successful IPOs

on

LB Pharmaceuticals Raises $285M in Upsized IPO to Fund Late-Stage Schizophrenia Drug Development

on

LB Pharmaceuticals Files for $228M IPO to Fund Phase III Schizophrenia Drug

on

LB Pharma's Novel Antipsychotic LB-102 Shows Promising Phase II Results for Schizophrenia

on

LB Pharma's Phase II Success Revitalizes Benzamide Antipsychotics for US Schizophrenia Treatment

on

LB Pharma's Novel Antipsychotic LB-102 Shows Promising Phase II Results for Schizophrenia

on

LB-102 Shows Promise as Potential First-in-Class Benzamide Antipsychotic for Schizophrenia

on

LB Pharma's Phase II Success Revives Promising Antipsychotic Class for US Patients with Schizophrenia

on

LB-102 Shows Promise as Potential First-in-Class Benzamide Antipsychotic for Schizophrenia in US

on

LB Pharma's Novel Antipsychotic LB-102 Shows Promise in Phase II Schizophrenia Trial

on

LB-102: Promising Phase 2 Results Revive Benzamide Antipsychotics for Schizophrenia Treatment in the US

on